-
State Food and Drug Administration: Medical devices such as Kangwei De, Bonmei Orthopedics, Edwards are being recalled
Time of Update: 2022-02-21
reported that due to a specific model and a specific batch of products, there was an error in the expiration date on the product label, the manufacturer Edwards Lifesciences LLC voluntarily recalled the valvuloplasty ring Tricuspid Annuloplasty Ring (Registration No.
Attachment: Medical Device Recall Incident Report Form ConvaTec Inc's voluntary recall of AQUACEL™ Foam Hydrofiber™ Dressing to ConvaTec Inc.
-
On the same day, a number of pharmaceutical companies released performance forecasts showing a pre-increase in net profit!
Time of Update: 2022-02-21
On the same day, Yabao Pharmaceutical's performance forecast showed that it is expected that the net profit attributable to shareholders of listed companies in 2021 will be 165 million to 190 million yuan, an increase of 53.
-
In 2022, innovative Chinese medicines will usher in more opportunities!
Time of Update: 2022-02-21
With the continuous release of favorable national policies, innovative traditional Chinese medicine drugs have also achieved rapid development as part of the traditional Chinese medicine industry .
-
These 5 pharmaceutical companies have been investigated by more than 100 institutions
Time of Update: 2022-02-21
Among the 16 listed companies that have been investigated by over 100 institutions, pharmaceutical companies account for About one-third of the total, reaching 5, namely Mindray Medical, Huadong Medicine, Puluo Pharmaceutical, Jiu'an Medical and Teyi Pharmaceutical .
-
The tax storm hit, 14 pharmaceutical companies were notified
Time of Update: 2022-02-21
Judging from the nature of the case, this violation mainly focused on "falsely issuing special VAT invoices", and 7 pharmaceutical companies violated the rules .
-
Haichuang Pharmaceutical's Phase 1 clinical trial of oral PROTAC therapy achieved the first patient dosing
Time of Update: 2022-02-19
On January 19, 2022, Haichuang Pharmaceutical announced that its drug candidate HP518, an oral protein-targeted degradation chimera (PROTAC) targeting androgen receptor (AR), achieved the first patient delivery in the Phase 1 clinical trial in Australia.
-
State Food and Drug Administration: Medical devices such as Kangwei De, Bonmei Orthopedics, Edwards are being recalled
Time of Update: 2022-02-19
Biomet Orthopedics voluntarily recalls revision femoral stems and accessories Arcos Modular Revision System , Shoulder System Comprehensive Shoulder System Zimmer (Shanghai) Medical International Trading Co.
Biomet Orthopedics voluntarily recalls revision femoral stems and accessories Arcos Modular Revision System , Shoulder System Comprehensive Shoulder System Zimmer (Shanghai) Medical International Trading Co.
-
Shiyao Yinhu Pharmaceutical Lidocaine Hydrochloride Injection Passes Consistency Evaluation of Generic Drugs
Time of Update: 2022-02-19
com China's public medical institutions terminal competition patternWith the over-evaluation of Lidocaine Hydrochloride Injection of CSPC Yinhu Pharmaceutical, there are currently 7 companies that have over-reviewed the product, including Kelun Pharmaceutical, Shandong Hualu Pharmaceutical, Shanghai Hefeng Pharmaceutical, Tianjin Jinyao Pharmaceutical, etc.
-
5 Chinese pharmaceutical companies authorized free generic copy of Merck's oral new crown drug molnupiravir
Time of Update: 2022-02-19
On the 20th, the Geneva Medicines Patent Pool announced that it had signed an agreement with 27 generic drug companies to produce Merck's oral COVID-19 antiviral drug molnupiravir, which will promote the use of this new crown oral drug at an acceptable burden for patients around the world .
-
2021 Hurun China Top 500 Freshly Released!
Time of Update: 2022-02-19
According to the company's statistics, from the perspective of Mindray Medical's accessible market, the business opportunities brought by the "Thousand County Project" in the next few years are expected to reach 10 billion yuan .
-
Kewan Pharmaceuticals completed the first patient administration of its anti-CD39 mAb in Phase 1 clinical trials in the United States
Time of Update: 2022-02-19
According to Kewang Medicine, by blocking the ATPase activity of the CD39 protein, ES002 can inhibit the production of adenosine while maintaining the level of extracellular ATP with a pro-inflammatory response, thereby restoring the anti-tumor microenvironment .
-
The development of the API industry continues to improve, and transformation and upgrading are becoming the general trend
Time of Update: 2022-02-19
In recent years, with the accelerating development of the pharmaceutical industry, the scale of China's API market has been growing .
According to this development trend, the scale of China's API industry is expected to exceed 250 billion yuan in 2022 .
-
Pharmacies have become a new trend in collecting and purchasing, and a large number of drugs will be reduced in price
Time of Update: 2022-02-19
Recently, the Henan Medical Insurance Bureau issued the "Notice on the Results of the Selected Results of the Centralized and Volume Purchase of Relevant Drug Retail Chain Enterprises" (hereinafter referred to as the "Notice") .
-
Good news for the pharmaceutical industry: 80% of the results are expected to be good, and many innovative drugs have been approved for clinical use
Time of Update: 2022-02-19
For example, on January 18, CDE's public information showed that the clinical trial application of TSN084 tablets of Taili Bio was approved by the Food and Drug Administration for the treatment of advanced or metastatic malignant tumors .
-
This week, a number of domestic new drugs were approved
Time of Update: 2022-02-19
announced that the marketing authorization application of the group's research product in the analgesic field, Oxycodone Naloxone Sustained-Release Tablets (LY021702), has also been accepted by the Center for Drug Evaluation of the State Drug Administration.
-
Another 4 pharmaceutical companies have pre-increased performance!
Time of Update: 2022-02-19
19% Jiu'an Medical released the 2021 annual report performance forecast today, and it is expected to achieve a net profit of 900 million to 1.
The net profit in the same period last year was 242 million yuan, and the basic earnings per share was 0.
-
Blowout of innovative traditional Chinese medicine!
Time of Update: 2022-02-19
Under a series of favorable policies, many securities institutions expressed their optimism about the development of innovative Chinese medicines .
-
In 2022, executives of pharmaceutical companies will change more frequently!
Time of Update: 2022-02-19
On the 18th, Marc CROUTON, Chief Commercial Officer of the Fresenius Kabi Management Committee, and Ulf JASSON, Executive Vice President of the Asia Pacific Region, announced to the employees a personnel appointment, which will be executed by Fresenius Kabi China from February 1, 2022.
-
breakthrough!
Time of Update: 2022-02-19
Another domestic CAR-T product obtained orphan drug qualification Recently, Heyuan Bio and the Chinese Academy of Medical Sciences Hematology Hospital jointly announced that its self-developed targeting CD19 CAR-T drug CNCT19 cell injection has obtained orphan drug qualification granted by the US FDA , for the treatment of acute lymphoblastic leukemia .
-
Under the steady growth of the market, the API industry will usher in new opportunities for development
Time of Update: 2022-02-19
In addition to the continuous growth of the market, according to Claricate data, China currently has 1,482 API production bases.
In this context, domestic API companies should accelerate innovation and promote the transformation and upgrading of the industry towards green, low-carbon and high-quality development .
